CBG - Revision history

Lazy at 08:19, 18 January 2025

2025-01-18T08:19:29Z

← Older revision		Revision as of 01:19, 18 January 2025
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=~~Cannabigerol~~ (~~CBG~~)		\|drug_name=Sativex (Nabiximols)
	\|~~overview~~=~~Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, is currently under investigation for its potential anti-cancer properties. Although not~~ FDA-approved~~, preclinical studies have explored CBG's ability to induce apoptosis, inhibit cell proliferation, and target cancer stem cells, highlighting its promise~~ in cancer research. While cannabinoids, including CBG, are generally regarded as safe, specific studies on its side effects remain limited, and detailed human clinical trials are needed to confirm its safety and efficacy. Ongoing research aims to determine its potential role in cancer treatment, particularly its impact on tumor progression and pathways involved in cancer development.		\|FDA_approval=Not FDA-approved in the United States; approved in several countries for spasticity due to multiple sclerosis
	~~\|FDA_approval=No (CBG is a cannabinoid compound under investigation~~; ~~not FDA-~~approved for ~~any condition)~~		\|used_for=Investigational use in glioblastoma for potential direct anti-tumor effects and symptom management
	\|used_for=Investigational use in ~~cancer research~~ for potential anti-tumor effects		\|clinical_trial_phase=Phase 2 clinical trial in 2021 indicated for glioblastoma
	\|clinical_trial_phase=~~Preclinical studies and early research~~		\|common_side_effects=Fatigue, dizziness, nausea, mouth irritation
	\|common_side_effects=~~Not specifically documented; cannabinoids are generally considered to have a favorable safety profile~~, ~~but specific studies on CBG's side effects are limited~~		\|OS_with=The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone
	\|OS_with=~~Not applicable; research is still~~ in ~~preclinical stages, focusing on cellular and animal models~~		\|PFS_with=Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival
	\|PFS_with=~~Not applicable~~; ~~ongoing studies aim to determine~~ the ~~potential impacts on tumor progression~~		\|usefulness_rating=4
	\|usefulness_rating=3		\|notes=In a notable 2021 trial, Sativex, combined with temozolomide, demonstrated an increase in overall survival among glioblastoma patients, marking a promising advancement in the use of cannabinoid-based therapies for cancer treatment. These results suggest Sativex may possess anti-tumor properties in addition to its symptom management potential, warranting further research to fully understand its therapeutic benefits and mechanism of action in glioblastoma.
	\|notes=~~Cannabigerol (CBG)~~, a ~~non-psychoactive cannabinoid found~~ in the ~~cannabis plant, has garnered attention in preclinical studies~~ for ~~its potential~~ anti-~~cancer~~ properties~~. Research has explored CBG's effects on various cancer cell lines, including~~ its ~~ability to induce apoptosis~~, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully ~~establish~~ its ~~efficacy~~ and ~~optimal use~~ in ~~cancer treatment~~.		\|treatment_category=Investigational Drugs
	\|treatment_category=~~Nutraceuticals~~
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=~~Cannabigerol (CBG)~~ is ~~generally considered safe~~, as it~~'s a non~~-~~psychoactive compound found~~ in the ~~cannabis plant. However~~, ~~specific studies~~ on ~~CBG’s side effects are limited owing to~~ the ~~fact that it~~ is in the ~~early stages of research~~. ~~Therefore, a rating of~~ 2 ~~is given~~, indicating ~~a low level of potential toxicity. However~~, ~~definitive conclusions about~~ its ~~toxicity can only be made after detailed human clinical trials have been conducted~~.		\|toxicity_explanation=The treatment has a toxicity level of 2 out of 5 which means it is fairly low in toxicity. The most commonly reported side effects include fatigue, dizziness, nausea, and mouth irritation. Please remember, these side effects do not occur in everyone and can be managed with the help of your healthcare team. More research is needed to fully understand the long-term effects of this treatment. As it is not FDA-approved in the United States, one has to monitor carefully when and if the treatment becomes available depending on the approval in their country.
	}}		\|overview=Sativex (Nabiximols) is an investigational drug not approved by the FDA in the United States but used in several countries to manage spasticity in multiple sclerosis and is being studied for its potential benefits in glioblastoma treatment. A 2021 Phase 2 clinical trial showed promising results, indicating an increase in overall survival when Sativex was used alongside temozolomide, although more research is needed to fully understand its effects and safety.}}

Lazy at 20:38, 25 December 2024

2024-12-25T20:38:46Z

← Older revision		Revision as of 13:38, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Cannabigerol (CBG)		\|drug_name=Cannabigerol (CBG)
	\| overview=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, is currently under investigation for its potential anti-cancer properties. Although not FDA-approved, preclinical studies have explored CBG's ability to induce apoptosis, inhibit cell proliferation, and target cancer stem cells, highlighting its promise in cancer research. While cannabinoids, including CBG, are generally regarded as safe, specific studies on its side effects remain limited, and detailed human clinical trials are needed to confirm its safety and efficacy. Ongoing research aims to determine its potential role in cancer treatment, particularly its impact on tumor progression and pathways involved in cancer development.		\|overview=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, is currently under investigation for its potential anti-cancer properties. Although not FDA-approved, preclinical studies have explored CBG's ability to induce apoptosis, inhibit cell proliferation, and target cancer stem cells, highlighting its promise in cancer research. While cannabinoids, including CBG, are generally regarded as safe, specific studies on its side effects remain limited, and detailed human clinical trials are needed to confirm its safety and efficacy. Ongoing research aims to determine its potential role in cancer treatment, particularly its impact on tumor progression and pathways involved in cancer development.
	\|FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)		\|FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)
	\|used_for=Investigational use in cancer research for potential anti-tumor effects		\|used_for=Investigational use in cancer research for potential anti-tumor effects

Lazy at 20:32, 25 December 2024

2024-12-25T20:32:30Z

← Older revision		Revision as of 13:32, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Cannabigerol (CBG)		\|drug_name=Cannabigerol (CBG)
			\| overview=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, is currently under investigation for its potential anti-cancer properties. Although not FDA-approved, preclinical studies have explored CBG's ability to induce apoptosis, inhibit cell proliferation, and target cancer stem cells, highlighting its promise in cancer research. While cannabinoids, including CBG, are generally regarded as safe, specific studies on its side effects remain limited, and detailed human clinical trials are needed to confirm its safety and efficacy. Ongoing research aims to determine its potential role in cancer treatment, particularly its impact on tumor progression and pathways involved in cancer development.
	\|FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)		\|FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)
	\|used_for=Investigational use in cancer research for potential anti-tumor effects		\|used_for=Investigational use in cancer research for potential anti-tumor effects

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:28:50Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:28, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.		\|notes=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.
	\|~~category~~=Nutraceuticals		\|treatment_category=Nutraceuticals
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.		\|toxicity_explanation=Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.
	}}		}}

Lazy at 18:06, 27 March 2024

2024-03-27T18:06:30Z

← Older revision		Revision as of 11:06, 27 March 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.		\|notes=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.
	\|category=Nutraceuticals ~~and herbals~~		\|category=Nutraceuticals
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.		\|toxicity_explanation=Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.
	}}		}}

Lazy at 16:54, 27 March 2024

2024-03-27T16:54:26Z

← Older revision		Revision as of 09:54, 27 March 2024
Line 11:		Line 11:
	\|category=Nutraceuticals and herbals		\|category=Nutraceuticals and herbals
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=Cannabigerol (CBG) is generally considered safe, as it's a non-psychoactive compound found in the cannabis plant. However, specific studies on CBG’s side effects are limited owing to the fact that it is in the early stages of research. Therefore, a rating of 2 is given, indicating a low level of potential toxicity. However, definitive conclusions about its toxicity can only be made after detailed human clinical trials have been conducted.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Cannabigerol (CBG) |FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition) |used_for=Investigational use in cancer research for potential anti-tumor effects |clinical_trial_phase=Preclinical studies and early research |common_side_effects=Not specifically documented; cannabinoids are generally considered to have a favorable safety profile, but specific studies on CBG's side effects are limited |O..."

2024-03-21T12:15:13Z

Created page with "{{TreatmentInfo |drug_name=Cannabigerol (CBG) |FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition) |used_for=Investigational use in cancer research for potential anti-tumor effects |clinical_trial_phase=Preclinical studies and early research |common_side_effects=Not specifically documented; cannabinoids are generally considered to have a favorable safety profile, but specific studies on CBG's side effects are limited |O..."

New page

{{TreatmentInfo
|drug_name=Cannabigerol (CBG)
|FDA_approval=No (CBG is a cannabinoid compound under investigation; not FDA-approved for any condition)
|used_for=Investigational use in cancer research for potential anti-tumor effects
|clinical_trial_phase=Preclinical studies and early research
|common_side_effects=Not specifically documented; cannabinoids are generally considered to have a favorable safety profile, but specific studies on CBG's side effects are limited
|OS_with=Not applicable; research is still in preclinical stages, focusing on cellular and animal models
|PFS_with=Not applicable; ongoing studies aim to determine the potential impacts on tumor progression
|usefulness_rating=3
|notes=Cannabigerol (CBG), a non-psychoactive cannabinoid found in the cannabis plant, has garnered attention in preclinical studies for its potential anti-cancer properties. Research has explored CBG's effects on various cancer cell lines, including its ability to induce apoptosis, inhibit cell proliferation, and potentially target cancer stem cells. While findings are promising, indicating CBG could influence pathways involved in cancer progression, conclusive evidence from human clinical trials is awaited to fully establish its efficacy and optimal use in cancer treatment.
|category=Nutraceuticals and herbals
|links=
}}